Real World Evidence 2022 Preview: Interview with Richard White

April 14, 2022

The Evidence Base is hosting its Real-World Evidence Live conference this June in London, which will focus on the use real-world evidence (RWE) in rare disease research and innovative therapy development. In the leadup to the event, The Evidence Base released an interview with speaker Richard White, COO at Oxford PharmaGenesis. In the interview, White discusses the importance of building trust in RWE among key healthcare stakeholders. In addition, White covers the impact of COVID-19 on regulatory decisionmaking.

According to White, “The RWE Registry, which was launched as part of the RWE Transparency Initiative, a partnership between ISPOR, ISPE (MD, US), the Duke-Margolis Center for Health Policy (WA, US) and the National Pharmaceutical Council (WA, US) and is the first global repository for RWE study protocols. This is an important step towards transparency in RWE because it will help us see whether planned RWE studies are eventually published and thus alleviate concerns over publication bias – where only the RWE studies that give the ‘right answer’ are submitted for publication. There’s no doubt that the mandate to posting randomized controlled trial (RCT) protocols on portals such as clinicaltrials.gov has increased trust in RCTs and the same should be true for RWE studies.”

To read the rest of the interview, click here.

(Source: The Evidence Base, March 30th, 2022)

Share This Story!